ERBB2 and gastric cancer: This study reports two patients with unresectable, HER2-positive (IHC-confirmed or ERBB2-amplified) advanced gastric cancer who received first-line therapy with the domestically developed anti-HER2 monoclonal antibody inetetamab combined with PD-1 inhibition and XELOX chemotherapy.